Skip to main content

Advertisement

Fig. 8 | BMC Cancer

Fig. 8

From: IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis

Fig. 8

BCL-2 inhibitor ABT-199 can efficiently cause apoptosis when combined with SMAC-mimetics Birinapant and AT-406. a: Cell viability of RKO after treatment with ABT-199, a specific inhibitor of BCL-2. Cells were either left untreated (ctr = control) or treated with different concentrations of ABT-199 for 48 and 72 h and the % percentage cell viability was measured by SRB. The values are the average of three independent experiments and are presented as fold change of the absorbance of treated/untreated cells, for each condition. Columns = % percentage of cell viability, bars = SD. b: Cell viability of cell line RKO after combined treatment with the SMAC-mimetic AT-406 and ABT-199. Cells were either left untreated (ctr = control) or treated with AT-406 combined with ABT-199 for 48 and 72 h and the % percentage cell viability was measured by SRB. c: Cell viability of cell line RKO after combined treatment with the SMAC-mimetic Birinapant and ABT-199. Cells were either left untreated (ctr = control) or treated with Birinapant and ABT-199 combination for 48 and 72 h. The values are the average of three independent experiments and are presented as fold change of the absorbance of treated/untreated cells, for each condition. Columns = % percentage of cell viability, bars = SD

Back to article page